Investment

Features

Fees Safety

Academy

Pluang+

Home/News Feed/Moderna shares rise over 16% on news of early hantavirus vaccine research.

MRNA

$68.49

+$0.21 +0.31%

Moderna shares rise over 16% on news of early hantavirus vaccine research.

Market News

11 May 2026

Proactive Investors

View Source

Bullish

Moderna's stock has gained more than 16% in five days following reports of its early-stage hantavirus vaccine development. The company is expanding its infectious disease research pipeline, although hantavirus's commercial potential is limited due to its low incidence. Interest in hantavirus surged after three cruise ship passengers recently died from the rare rodent-borne disease. Unlike respiratory viruses, hantavirus spreads mainly through contact with infected rodents, not person-to-person transmission.

More News (MRNA)

Moderna's Q2 report expected uneventful; key focus on COVID vaccine demand and Phase III melanoma data.

Moderna is set to report its Q2 results on July 31, with expectations of a modest revenue decline due to seasonal COVID-19 vaccine demand. Jefferies forecasts a loss of $1.99 per share on about $100 million revenue, down from Q1's $389 million. Inves...

Company Fundamentals

Neutral

1 day ago